Research Progress of EZH2 in Tumors and Translational Perspectives  

作　　者：Yu Tian Hu-Li Li You-Fu Pan 

机构地区：[1]Department of Medical Genetics,Zunyi Medical University,Zunyi 563000,Guizhou,China

出　　处：《Proceedings of Anticancer Research》2025年第2期43-55,共13页抗癌研究

基　　金：supported by the National Natural Science Foundation of China(32360166,31760321).

摘　　要：Enhancer of zeste homolog 2(EZH2)is a key epigenetic regulatory protein and enzyme catalytic subunit of the polycomb repressor complex 2(PRC2),responsible for catalyzing the trimethylation of histone H3K27 and subsequent repression of gene transcription.Abnormal EZH2 expression or mutation is associated with various cancers,particularly lymphoma,and breast and prostate cancer.EZH2 has been investigated as an important target in cancer therapy and potential EZH2-targeted drugs have been developed.This article reviews the research progress on the mechanism of transcriptional regulation of EZH2 and the development and clinical use of some inhibitors targeting EZH2.

关 键 词：EZH2 Polycomb repressor complex 2 Cell signaling INHIBITOR 

分 类 号：R730.5[医药卫生—肿瘤] R730.2[医药卫生—临床医学]